Home > Gastroenterology > Combination checkpoint and VEGF inhibitors now first-line treatment for advanced liver cancer

Combination checkpoint and VEGF inhibitors now first-line treatment for advanced liver cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Oncology
Reuters Health - 28/10/2020 - Combination therapy with the checkpoint inhibitor (CPI) atezolizumab and the vascular endothelial growth factor inhibitor (VEGFi) bevacizumab emerged as the standard of care for advanced liver cancer in a systematic review and network meta-analysis. "Our findings establish the most effective treatment sequence in advanced hepatocellular cancer (HCC) and should be integrated in practice," Dr. Tanios Bekaii-Saab of Mayo Clinic in Phoenix told Reuters Health by email. That said, he added, "Although these findings facilitate current care for patients with advanced HCC, future trials need to focus on other potential combinations, sequencing, and optimizing sequencing strategies following CPI/VEGFi exposure." As reported in JAMA Oncology, the team searched the literature from inception through March 2020 for phase 3 trials evaluating various VEGFis, CPIs, and their combinations in advanced HCC, either as first-line treatment or for ref...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on